Intelligence · Clinical Pipeline

Phase III Pipeline Programs

Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Programs
5,427

Quick answer

NovaPharmaNews tracks 5,427 phase iii pharmaceutical pipeline programs from ClinicalTrials.gov. Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Top sponsors

Page 64 of 114

  1. PEG-Interferon a-2b + Ribavirin

    Universal Integrated

    Chronic Hepatitis C Infection in HIV-Infected Persons

    phase 3 small molecule completed

    1 trial
  2. PEG-interferon-Alfa-2A

    Hospital Authority, Hong Kong

    Chronic Hepatitis B

    phase 3 small molecule active

    1 trial
  3. PEGASPARGASE

    Pari Pharma GmbH

    This is a prospective, French, multicenter, open-label, design, stratified on the immunophenotypic characterization (B- or T- lineage) and the patient risk group, that aims at evaluating the efficacy and the tolerance of different schedules of pegaspargase in patients from 12 months to less than 18 years newly diagnosed with standard/medium-risk ALL

    phase 3 small molecule active

    1 trial
  4. PEGCETACOPLAN (APL-2)

    Apellis Europe B.V.

    Geographic Atrophy Secondary to Age-related Macular Degeneration

    phase 3 small molecule completed

    1 trial
  5. PEGFILGRASTIM , PACLITAXEL , DOXORUBICIN , Rinatabart Sesutecan, GEMCITABINE , TOPOTECAN

    Genmab A/S

    Platinum-resistant Ovarian Cancer

    phase 3 small molecule active

    1 trial
  6. PEGylated Recombinant Factor VIII

    Takeda

    Hemophilia A

    phase 3 mab completed

    2 trials
  7. PEGylated Recombinant factor VIII (rFVIII)

    Takeda

    Hemophilia A

    phase 3 mab completed

    1 trial
  8. PEMBROLIZUMAB

    Ningbo Cancer Hospital

    Squamous cell carcinoma of head and neck

    phase 3 small molecule active

    1 trial
  9. PEMBROLIZUMAB

    Ningbo Cancer Hospital

    Patient with early triple-negative breast cancer (TNBC) achieving pathologic complete response (pCR) after neoadjuvant systemic chemotherapy and pembrolizumab.

    phase 3 small molecule active

    1 trial
  10. PEMBROLIZUMAB , Adagloxad simolenin with adjuvant, CAPECITABINE

    Lacuna Pharma Pty Ltd

    Triple Negative Breast Cancer

    phase 3 small molecule active

    1 trial
  11. PEMBROLIZUMAB , BNT113

    BioNTech SE

    Unresectable head and neck squamous cell carcinoma, metastatic head and neck cancer, recurrent head and neck cancer

    phase 3 small molecule active

    1 trial
  12. PEMBROLIZUMAB , IMFINZI 50 mg/mL concentrate for solution for infusion., JZP598, Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., Gemcitabin Hikma 38 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Jazz Pharmaceuticals Ireland Limited

    BTC - Biliary Tract Cancer

    phase 3 small molecule active

    1 trial
  13. PEMBROLIZUMAB , Matching placebo, EIK1001 solution for injection 1.0 mg/mL free base equivalent

    Eikon Therapeutics

    Advanced Melanoma

    phase 3 small molecule active

    1 trial
  14. PEMBROLIZUMAB , Placebo to match ly, ENFORTUMAB VEDOTIN

    Eli Lilly Co.

    Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis

    phase 3 small molecule active

    1 trial
  15. PEMBROLIZUMAB, IMFINZI 50 mg/mL concentrate for solution for infusion., CARBOPLATIN, INFLIXIMAB, PACLITAXEL, MYCOPHENOLATE MOFETIL, GEMCITABINE, Datopotamab deruxtecan, PACLITAXEL ALBUMIN-BOUND

    AstraZeneca AB

    Triple-negative Breast Cancer

    phase 3 small molecule active

    1 trial
  16. PEMBROLIZUMAB, PEMETREXED DISODIUM, CISPLATIN, PEMETREXED DISODIUM, Relatlimab + Nivolumab Fixed Dose Combination (FDC), CARBOPLATIN

    Bristol-Myers Squibb Australia Pty Ltd

    Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial
  17. PEMETREXED , GEMCITABINE , PACLITAXEL , CISPLATIN , CARBOPLATIN , IMFINZI 50 mg/mL concentrate for solution for infusion.

    Partner Therapeutics Limited

    Stage IIB-IIIB (N2) resectable non small cell lung cancer

    phase 3 small molecule active

    1 trial
  18. PEMETREXED , KEYTRUDA 25 mg/mL concentrate for solution for infusion, PACLITAXEL ALBUMIN-BOUND, CARBOPLATIN , PACLITAXEL , pembrolizumab, CISPLATIN

    Merck Sharp and Dohme

    Metastatic (stage IV) squamous or nonsquamous non-small cell lung cancer (NSCLC).

    phase 3 small molecule active

    1 trial
  19. PEMETREXED , KEYTRUDA 25 mg/mL concentrate for solution for infusion., CARBOPLATIN

    Pari Pharma GmbH

    Adult patients with stage IV non squamous non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial
  20. PEMETREXED, PALONOSETRON, Adagrasib, PEMBROLIZUMAB, CARBOPLATIN, tablets, CISPLATIN

    Bristol-Myers Squibb Australia Pty Ltd

    Locally Advanced or Metastatic Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial
  21. PEMETREXED, PEMBROLIZUMAB, CISPLATIN, PACLITAXEL, PACLITAXEL ALBUMIN-BOUND, CARBOPLATIN

    Ningbo Cancer Hospital

    Advanced (stage IIIB/IIIC/IV) NSCLC patients eligible for treatment with a PD-1 antagonist (pembrolizumab) according to the European Marketing Authorisation in a first line

    phase 3 small molecule active

    1 trial
  22. PEMETREXED, VINORELBINE, Rilvegostomig, MYCOPHENOLATE MOFETIL, ETOPOSIDE, CISPLATIN, INFLIXIMAB, CARBOPLATIN, Datopotamab deruxtecan

    AstraZeneca AB

    Stage I adenocarcinoma non-small cell lung cancer (NSCLC) with ctDNA-positive result or high-risk pathological feature

    phase 3 small molecule active

    1 trial
  23. PENTHROX 99,9%, liquide pour inhalation par vapeur de 3 mL, MORPHINE

    Pari Pharma GmbH

    Acute Myocardial Infarction

    phase 3 small molecule active

    1 trial
  24. PF-02341066

    Pfizer

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule completed

    2 trials
  25. PF-05280014

    Pfizer

    Metastatic Breast Cancer

    phase 3 mab completed

    1 trial
  26. PF-05280586

    Pfizer

    Follicular Lymphoma

    phase 3 mab completed

    1 trial
  27. PF-06438179

    Pfizer

    Rheumatoid Arthritis

    phase 3 mab completed

    1 trial
  28. PF-06651600 Induction Dose

    Pfizer

    Alopecia Areata

    phase 3 small molecule completed

    1 trial
  29. PF-06801591

    Pfizer

    Non-muscle Invasive Bladder Cancer

    phase 3 small molecule active

    1 trial
  30. PF-06821497, Tablet to match Placebo for PF-06821497 250mg, PF-06821497, ENZALUTAMIDE, Tablet to match Placebo for PF-06821497 125mg

    Pfizer Australia Pty Ltd

    METASTATIC CASTRATION RESISTANT PROSTATE CANCER

    phase 3 small molecule active

    1 trial
  31. PF-07275315 dose 1

    Pfizer

    Moderate to Severe Chronic Obstructive Pulmonary Disease

    phase 3 small molecule active

    1 trial
  32. PF-07321332

    Pfizer

    COVID-19

    phase 3 small molecule completed

    2 trials
  33. PF614 capsule

    Ensysce Biosciences

    Postoperative Pain, Acute

    phase 3 small molecule active

    1 trial
  34. PG-011 nasal spray 0.6%(twice daily)

    Prime Medicine

    Seasonal Allergic Rhinitis

    phase 3 small molecule active

    1 trial
  35. PG-011Gel

    Prime Medicine

    Atopic Dermatitis

    phase 3 small molecule active

    1 trial
  36. PGET

    Atrium Therapeutics

    Osteoarthritis

    phase 3 other terminated

    1 trial
  37. PH94B

    Vistagen Therapeutics

    Social Anxiety Disorder

    phase 3 small molecule terminated

    1 trial
  38. PH94B Nasal Spray

    Vistagen Therapeutics

    Social Anxiety Disorder

    phase 3 small molecule terminated

    2 trials
  39. PHENOXYMETHYLPENICILLIN, PHENOXYMETHYLPENICILLIN

    Tour Hekla

    Recurrent Erysipelas in lower limbs

    phase 3 small molecule active

    1 trial
  40. PIMECROLIMUS , Amlitelimab, Matched placebo for test, Amlitelimab, -, TACROLIMUS

    Sanofi-aventis Healthcare Pty Ltd

    Dermatitis atopic

    phase 3 small molecule active

    1 trial
  41. PIMECROLIMUS , Amlitelimab, Placebo, Amlitelimab, -, TACROLIMUS

    Sanofi-aventis Healthcare Pty Ltd

    Dermatitis atopic

    phase 3 small molecule active

    1 trial
  42. PIPERACILLIN AND BETA-LACTAMASE INHIBITOR , NEGABAN 2 g, poudre pour solution injectable/pour perfusion, MEROPENEM ARROW 1 g, poudre pour solution injectable / pour perfusion

    Pari Pharma GmbH

    patients hospitalized in ICU with ESBL-producing Enterobacteriaceae severe infection

    phase 3 small molecule active

    1 trial
  43. PIPERACILLINE TAZOBACTAM VIATRIS 4 g/0,5 g, poudre pour solution pour perfusion, CEFAZOLIN, Placebo de Cefazoline / Piperaciline / Tazobactam

    Pari Pharma GmbH

    Excision-autograft surgery in burn patient

    phase 3 small molecule active

    1 trial
  44. PIRTOBRUTINIB, IBRUTINIB, PIRTOBRUTINIB, IBRUTINIB

    Wuhan Createrna Science and Technology Co., Ltd

    Mantle cell lymphoma

    phase 3 small molecule active

    1 trial
  45. PIRTOBRUTINIB, IDELALISIB, RITUXIMAB, BENDAMUSTINE HYDROCHLORIDE, PIRTOBRUTINIB, IDELALISIB

    Wuhan Createrna Science and Technology Co., Ltd

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial
  46. PIRTOBRUTINIB, RITUXIMAB, PIRTOBRUTINIB, BENDAMUSTINE

    Wuhan Createrna Science and Technology Co., Ltd

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial
  47. PL1 - Lyophilisate and solvent for solution for injection, sotatercept

    Lacuna Pharma Pty Ltd

    Pulmonary Arterial Hypertension (PAH)

    phase 3 small molecule active

    1 trial
  48. PL1 - Placebo to match losmapimod tablets are tablets for oral administration and visually match the active losmapimod tablets, 15 mg., Losmapimod

    Fulcrum Therapeutics

    Facioscapulohumeral Muscular Dystrophy (FSHD)

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many Phase III pipeline programs are in the directory?

5,427 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs